Drug Profile
Desmoteplase
Alternative Names: Bat-PA; Bat-tPA; Desmodus salivary plasminogen activator; DSPA; DSPA-A-1; DSPA-alpha-1; PN-01; rDSPA-alpha-1; SH-576; ZK-152387Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma
- Developer Lundbeck A/S; PAION
- Class Plasminogen activator enzymes; Recombinant proteins; Thrombolytics
- Mechanism of Action Plasminogen activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Myocardial infarction; Stroke; Thromboembolism
Most Recent Events
- 17 Dec 2014 Discontinued - Phase-III for Stroke in USA, Hungary, United Kingdom, Sweden, South Africa, Norway, Mexico, Italy, Ireland, Finland, Denmark, Chile, Brazil, Belgium, Vietnam, Thailand, Taiwan, Switzerland, Spain, Poland, Philippines, the Netherlands, South Korea, India, Germany, France, Estonia, Austria, Japan, Singapore, Hong Kong, Australia and Canada (IV)
- 25 Oct 2014 Additional efficacy and adverse events data from the phase III DIAS-3 trial in Stroke released by Lundbeck
- 08 Oct 2014 Lundbeck A/S terminates the phase III DIAS-4 trial in Stroke in USA, Belgium, Brazil, Canada, Chile, Denmark, Estonia, Finland, Ireland, Italy, Mexico, Norway, South Africa, Spain, Sweden and United Kingdom (NCT00856661)